Koper – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 03 Aug 2026 10:42:15 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Koper – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin https://clinicaltrials.eu/trial/a-study-comparing-cagrilintide-and-semaglutide-combination-to-semaglutide-cagrilintide-and-placebo-in-adults-with-type-2-diabetes-on-metformin/ Mon, 03 Aug 2026 10:42:15 +0000 https://clinicaltrials.eu/trial/a-study-comparing-cagrilintide-and-semaglutide-combination-to-semaglutide-cagrilintide-and-placebo-in-adults-with-type-2-diabetes-on-metformin/ This study is looking at people with type 2 diabetes whose blood sugar levels are not well controlled with their current medication. Type 2 diabetes is a condition where the body does not properly use insulin, a hormone that helps control blood sugar levels. The study will test different combinations and doses of medications given as injections under the skin. These medications include cagrilintide, semaglutide, a combination of both called CagriSema, and placebo. Some participants may also continue taking their regular diabetes medications, which could include metformin taken by mouth, with or without a type of medication called an SGLT2 inhibitor such as dapagliflozin.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

]]> Study on Lowering Cholesterol with Rosuvastatin or Rosuvastatin/Ezetimibe in Patients at High or Very High Risk of Cardiovascular Disease with High Cholesterol https://clinicaltrials.eu/trial/study-on-lowering-cholesterol-with-rosuvastatin-or-rosuvastatin-ezetimibe-in-patients-at-high-or-very-high-risk-of-cardiovascular-disease-with-high-cholesterol/ Mon, 03 Aug 2026 10:22:20 +0000 https://clinicaltrials.eu/trial/study-on-lowering-cholesterol-with-rosuvastatin-or-rosuvastatin-ezetimibe-in-patients-at-high-or-very-high-risk-of-cardiovascular-disease-with-high-cholesterol/ This clinical trial is focused on studying the effects of treatments for hyperlipidemia, a condition characterized by high levels of fats, such as cholesterol, in the blood. The study will use medications containing rosuvastatin and a combination of rosuvastatin and ezetimibe. These medications are designed to help lower levels of low-density lipoprotein cholesterol (LDL-C), often referred to as “bad” cholesterol, in patients who are at high or very high risk of cardiovascular disease.

The purpose of the study is to evaluate how effective and safe these treatments are in achieving specific cholesterol level goals over a period of 12 weeks. Participants will be divided into different groups, with some receiving rosuvastatin alone and others receiving the combination of rosuvastatin and ezetimibe. The study will monitor changes in cholesterol levels at different intervals, specifically after 4, 8, and 12 weeks of treatment.

Throughout the study, participants will take the medications orally in the form of film-coated tablets. The trial aims to determine the proportion of patients who reach their LDL-C goals, which are set based on their risk levels for cardiovascular disease. The study will also assess the overall changes in cholesterol and other related blood fats to understand the effectiveness of the treatments. Participants’ adherence to the treatment regimen will be monitored to ensure accurate results.

]]> Zdravstveni dom Koper https://clinicaltrials.eu/site/zdravstveni-dom-koper/ Tue, 02 Jun 2026 09:57:12 +0000 https://clinicaltrials.eu/site/zdravstveni-dom-koper/ Zdravstveni Dom Koper Casa Della Sanita Capodistria https://clinicaltrials.eu/site/zdravstveni-dom-koper-casa-della-sanita-capodistria/ Thu, 30 Apr 2026 09:19:33 +0000 https://clinicaltrials.eu/site/zdravstveni-dom-koper-casa-della-sanita-capodistria/